Skip to main content
SpringerLink
Log in

Is genetic screening for hemochromatosis worthwhile?

  • Review
  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

Hereditary hemochromatosis is an iron overload disorder and is the most common recessive disease in Caucasians. About 80% of hemochromatosis patients are homozygous for the C282Y mutation in the HFE gene. Since iron accumulation can be prevented by phlebotomy, there is increasing interest in screening populations for hemochromatosis. Hemochromatosis is a disease that meets all the criteria for screening as set by the World Health Organization (WHO) or the US preventive services task force criteria for a screening program. However, there is no consensus on the value of a screening program for hemochromatosis. Moreover, there is no agreement on whether this screening should be based on the phenotype i.e. biochemical levels of serum iron parameters or on the genotype i.e. based on the presence of mutations in the HFE gene. Other important concerns are the lack of important data in evaluating screening as well as the psychosocial impact of a screening program. The present review analyses the current situation from a genetic-epidemiological perspective. We conclude that general population screening may be helpful to identify high-risk groups or individuals in the early stage of the disease so that treatment can be started. We suggest a two-phase screening program based on the first instance on serum iron levels and then a genetic test to only those with elevated serum iron parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000; 33: 485–504.

    Article  CAS  PubMed  Google Scholar 

  2. Powell LW, Leggett BA, Crawford DHG. Hemochromatosis and other iron storage disorders. In: Schiff ER, Sorrel MF, Maddrey WC (eds), Schiff's diseases of the liver. Philadelphia: Lippincott-Raven, 1999: 1107–1130.

    Google Scholar 

  3. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355–1362.

    CAS  PubMed  Google Scholar 

  4. Leggett BA, Halliday JW, Brown NN, Bryant S, Powell LW. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol 1990; 74: 525–530.

    CAS  PubMed  Google Scholar 

  5. Baer DM, Simons JL, Staples RL, Rumore GJ, Morton CJ. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med 1995; 98: 464–468.

    Article  CAS  PubMed  Google Scholar 

  6. Cardoso EM, Stal P, Hagen K, et al. HFE mutations in patients with hereditary haemochromatosis in Sweden. J Intern Med 1998; 243: 203–208.

    Article  CAS  PubMed  Google Scholar 

  7. Powell L, Jazwinska E, Halliday J. Primary iron overload. In: Brock J, Halliday J, Pippard M, Powell L (eds), Iron metabolism in health and disease. London: Saunders, 1994: 227–270.

    Google Scholar 

  8. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996; 245: 139–200.

    Article  CAS  PubMed  Google Scholar 

  9. Finch S, Finch C. Idiopathic hemochromatosis, an iron storage disease. A: Iron metabolism in hemochromatosis. Medicine 1955; 34: 381–430.

    CAS  PubMed  Google Scholar 

  10. Scheuer P, Williams R, Muir A. Hepatic pathology in relatives of patients with hemochromatosis. J Pathol Bacteriol 1962; 84: 53–64.

    Article  CAS  PubMed  Google Scholar 

  11. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986; 6: 24–29.

    CAS  PubMed  Google Scholar 

  12. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408.

    Article  CAS  PubMed  Google Scholar 

  13. Powell LW. Diagnosis of hemochromatosis. Semin Gastrointest Dis 2002; 13: 80–88.

    PubMed  Google Scholar 

  14. Sheldon J. Hemochromatosis. London: Oxford University Press; 1935.

    Google Scholar 

  15. Saddi R, Feingold J. Hemochromatose idiopathique. Maladie recessive autosomique. Rev Fr Etud Clin Biol 1969; 14: 238–251.

    CAS  PubMed  Google Scholar 

  16. Saddi R, Feingold J. Idiopathic haemochromatosis: An autosomal recessive disease. Clin Genet 1974; 5: 234–241.

    CAS  PubMed  Google Scholar 

  17. Simon M, Alexandre JL, Bourel M, Le Marec B, Scordia C. Heredity of idiopathic haemochromatosis: A study of 106 families. Clin Genet 1977; 11: 327–341.

    CAS  PubMed  Google Scholar 

  18. Simon M, Hespel JP, Fauchet R, et al. Heredite recessive de l'hemochromatose idiopathique: deux observations de transmission pseudo-dominante reconnue comme recessive par l'etude de la surcharge en fer et des genotypes HLA dans les familles. Nouv Presse Med 1979; 8: 421–424.

    CAS  PubMed  Google Scholar 

  19. Simon M, Alexandre JL, Fauchet R, Genetet B, Bourel M. The genetics of hemochromatosis. Prog Med Genet 1980; 4: 135–168.

    CAS  PubMed  Google Scholar 

  20. Barton JC, Shih WW, Sawada-Hirai R, et al. Genetic and clinical description of hemochromatosis probands and heterozygotes: Evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis 1997; 23: 135–145.

    Article  CAS  PubMed  Google Scholar 

  21. Brissot P, Moirand R, Jouanolle AM, et al. A genotypic study of 217 unrelated probands diagnosed as 'genetic hemochromatosis' on 'classical' phenotypic criteria. J Hepatol 1999; 30: 588–593.

    Article  CAS  PubMed  Google Scholar 

  22. Moirand R, Jouanolle AM, Brissot P, Le Gall JY, David V, Deugnier Y. Phenotypic expression of HFE mutations: A French study of 1110 unrelated ironoverloaded patients and relatives. Gastroenterology 1999; 116: 372–377.

    Article  CAS  PubMed  Google Scholar 

  23. Whitfield JB, Cullen LM, Jazwinska EC, et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet 2000; 66: 1246–1258.

    Article  CAS  PubMed  Google Scholar 

  24. Beutler E, Gelbart T, West C, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996; 22: 187–194.

    CAS  PubMed  Google Scholar 

  25. Borot N, Roth M, Malfroy L, et al. Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients. Immunogenetics 1997; 45: 320–324.

    Article  CAS  PubMed  Google Scholar 

  26. Jazwinska EC, Powell LW. Hemochromatosis and 'HLA-H': Definite! Hepatology 1997; 25: 495–496.

    CAS  PubMed  Google Scholar 

  27. Pointon JJ, Wallace D, Merryweather-Clarke AT, Robson KJ. Uncommon mutations and polymorphisms in the hemochromatosis gene. Genet Test 2000; 4: 151–161.

    CAS  PubMed  Google Scholar 

  28. Parkkila S, Waheed A, Britton RS, et al. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci USA 1997; 94: 2534–2539.

    CAS  PubMed  Google Scholar 

  29. Lebron JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998; 93: 111–123.

    Article  CAS  PubMed  Google Scholar 

  30. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275–278.

    CAS  PubMed  Google Scholar 

  31. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: A HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001; 154: 193–206.

    Article  CAS  PubMed  Google Scholar 

  32. Jouanolle AM, Gandon G, Jezequel P, et al. Haemochromatosis and HLA-H. Nat Genet 1996; 14: 251–252.

    Article  CAS  PubMed  Google Scholar 

  33. Cazzola M, Ascari E, Barosi G, et al. Juvenile idiopathic haemochromatosis: A life-threatening disorder presenting as hypogonadotropic hypogonadism. Hum Genet 1983; 65: 149–154.

    Article  CAS  PubMed  Google Scholar 

  34. Camaschella C, Roetto A, Cicilano M, et al. Juvenile and adult hemochromatosis are distinct genetic disorders. Eur J Hum Genet 1997; 5: 371–375.

    CAS  PubMed  Google Scholar 

  35. Charlton RW, Abrahams C, Bothwell TH. Idiopathic hemochromatosis in young subjects. Clinical, pathological, and chemical findings in four patients. Arch Pathol 1967; 83: 132–140.

    CAS  PubMed  Google Scholar 

  36. Cazzola M, Cerani P, Rovati A, Iannone A, Claudiani G, Bergamaschi G. Juvenile genetic hemochromatosis is clinically and genetically distinct from the classical HLA-related disorder. Blood 1998; 92: 2979–2981.

    CAS  PubMed  Google Scholar 

  37. Kelly AL, Rhodes DA, Roland JM, Schofield P, Cox TM. Hereditary juvenile haemochromatosis: A genetically heterogeneous life-threatening iron-storage disease. QJM 1998; 91: 607–618.

    Article  CAS  PubMed  Google Scholar 

  38. Roetto A, Totaro A, Cazzola M, et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999; 64: 1388–1393.

    Article  CAS  PubMed  Google Scholar 

  39. Papanikolaou G, Papaioannou M, Politou M, et al. Genetic heterogeneity underlies juvenile hemochromatosis phenotype: Analysis of three families of northern greek origin. Blood Cells Mol Dis 2002; 29: 168–173.

    Article  CAS  PubMed  Google Scholar 

  40. Camaschella C, Roetto A, Cali A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14–15.

    CAS  PubMed  Google Scholar 

  41. Roetto A, Daraio F, Alberti F, et al. Hemochromatosis due to mutations in transferrin receptor 2. Blood Cells Mol Dis 2002; 29: 465–470.

    CAS  PubMed  Google Scholar 

  42. Pietrangelo A, Montosi G, Totaro A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999; 341: 725–732.

    Article  CAS  PubMed  Google Scholar 

  43. Montosi G, Donovan A, Totaro A, et al. Autosomaldominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108: 619–623.

    Article  CAS  PubMed  Google Scholar 

  44. Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28: 213–214.

    Article  CAS  PubMed  Google Scholar 

  45. Devalia V, Carter K, Walker AP, et al. Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). Blood 2002; 100: 695–697.

    Article  CAS  PubMed  Google Scholar 

  46. Roetto A, Merryweather-Clarke AT, Daraio F, et al. A valine deletion of ferroportin 1: A common mutation in hemochromastosis type 4. Blood 2002; 100: 733–734.

    Article  CAS  PubMed  Google Scholar 

  47. Wallace DF, Pedersen P, Dixon JL, et al. Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. Blood 2002; 100: 692–694.

    Article  CAS  PubMed  Google Scholar 

  48. Townsend A, Drakesmith H. Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload. Lancet 2002; 359: 786–790.

    Article  CAS  PubMed  Google Scholar 

  49. Kato J, Fujikawa K, Kanda M, et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001; 69: 191–197.

    Article  CAS  PubMed  Google Scholar 

  50. Baer D. Hereditary iron overload and African Americans. Am J Med 1996; 101: 5–8.

    Article  CAS  PubMed  Google Scholar 

  51. Gangaidzo IT, Moyo VM, Saungweme T, et al. Iron overload in urban Africans in the 1990s. Gut 1999; 45: 278–283.

    CAS  PubMed  Google Scholar 

  52. Beutler E, Gelbart T. HLA-H mutations in the Ashkenazi Jewish population. Blood Cells Mol Dis 1997; 23: 95–98.

    CAS  PubMed  Google Scholar 

  53. Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: Gene discovery and its implications for population-based screening. JAMA 1998; 280: 172–178.

    CAS  PubMed  Google Scholar 

  54. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med 1993; 328: 1616–1620.

    Article  CAS  PubMed  Google Scholar 

  55. Haddow JE, Ledue TB. Preventing manifestations of hereditary haemochromatosis through population based screening. J Med Screen 1994; 1: 16–21.

    CAS  PubMed  Google Scholar 

  56. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: A unifying analysis of 107 published intervention trials. J Med Screen 1996; 3: 178–184.

    CAS  PubMed  Google Scholar 

  57. Wilson J, Junger G. The principle and practise of screening for disease. Public Health Papers WHO 1968; 34: 26–29.

    Google Scholar 

  58. US preventive services task force. Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force. 2nd edn. Baltimore, MD, 1969, pp. 231–246.

  59. Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: Decision analysis model based on a 30-year database. Gastroenterology 1995; 109: 177–188.

    Article  CAS  PubMed  Google Scholar 

  60. Tavill A. Screening for hemochromatosis: Phenotyping or genotyping or both→Am J Gastroenterol 1999; 94: 1430–1433.

    Article  CAS  PubMed  Google Scholar 

  61. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211–218.

    Article  PubMed  Google Scholar 

  62. Burt MJ, George PM, Upton JD, et al. The significance of haemochromatosis gene mutations in the general population: Implications for screening. Gut 1998; 43: 830–836.

    CAS  PubMed  Google Scholar 

  63. Adams P, Valberg L. Screening blood donors fot hereditery hemochromatosis: Decision analysis model comparing genotyping to phenotyping. Am J Gastroenteroly 1999; 94: 1593–1600.

    CAS  Google Scholar 

  64. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 1994; 11(154): 769–776; Allen K, Warner B, Delatyecki M. Clinical hemochromatosis in HFE mutation carriers. Lancet 2002; 360: 412–413.

    Google Scholar 

  65. Khoury MJ. Human genome epidemiology: Translating advances in human genetics into population-based data for medicine and public health. Genet Med 1999; 1: 71–73.

    CAS  PubMed  Google Scholar 

  66. Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N Engl J Med 2000; 343: 141–144.

    Article  CAS  PubMed  Google Scholar 

  67. Njajou OT, Houwing-Duistermaat JJ, Osborne R, et al. A population-based study of the effect of the HFE C282Y and H63D mutations on iron metabolism. Eur J Hum Gen 2003; 11: 225–231.

    CAS  Google Scholar 

  68. Vogelstein B, Kinzler KW. The genetic basis of human cancer. New York: McGraw-Hill, 1998.

    Google Scholar 

  69. Bassett ML, Wilson SR, Cavanaugh JA. Penetrance of HFE-related hemochromatosis in perspective. Hepatology 2002; 36: 500–503.

    Google Scholar 

  70. Cox T, Rochette J, Camaschella C, Walker A, K R. Clinical hemochromatosis in HFE mutation carriers. Lancet 2002; 360: 412.

    Article  PubMed  Google Scholar 

  71. Poullis A, Moodie SJ, Maxwell JD. Clinical hemochromatosis in HFE mutation carriers. The Lancet 2002; 360: 411.

    Article  CAS  Google Scholar 

  72. Njajou OT, Hollander M, Koudstaal PJ, et al. Mutations in HFE gene and stroke. Stroke 2002; 33: 2363–2366.

    Article  CAS  PubMed  Google Scholar 

  73. Njajou OT, Alizadeh BZ, Vaessen N, et al. The role of hemochromatosis C282Y and H63D mutations in type 2 diabetes. Diabetes Care 2002; 25: 2112–2113.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Genetic Epidemiology Unit, Departments of Epidemiology & Biostatistics and Clinical Genetics, Erasmus Medical Centre, P.O. BOX 1738, 3000 DR, Rotterdam, The Netherlands

    Omer T. Njajou, Behrooz Z. Alizadeh & Cornelia M. van Duijn

Authors
  1. Omer T. Njajou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Behrooz Z. Alizadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cornelia M. van Duijn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cornelia M. van Duijn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Njajou, O.T., Alizadeh, B.Z. & van Duijn, C.M. Is genetic screening for hemochromatosis worthwhile?. Eur J Epidemiol 19, 101–108 (2004). https://doi.org/10.1023/B:EJEP.0000017664.96394.b9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:EJEP.0000017664.96394.b9

Search

Navigation